The Rgr oncogene induces tumorigenesis in transgenic mice

To study the oncogenic potential of Rgr in vivo, we have generated several transgenic Rgr mouse lines, which express the oncogene under the control of different promoters. These studies revealed that Rgr expression leads to the generation of various pathological alterations, including fibrosarcomas,...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 64; no. 17; pp. 6041 - 6049
Main Authors JIMENEZ, Maria, PEREZ DE CASTRO, Ignacio, BENET, Marta, GARCIA, Juan F, INGHIRAMI, Giorgio, PELLICER, Angel
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 01.09.2004
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To study the oncogenic potential of Rgr in vivo, we have generated several transgenic Rgr mouse lines, which express the oncogene under the control of different promoters. These studies revealed that Rgr expression leads to the generation of various pathological alterations, including fibrosarcomas, when its transgenic expression is restricted to nonlymphoid tissues. Moreover, the overall incidence and latency of fibrosarcomas were substantially increased and shortened, respectively, in a p15INK4b-defective background. More importantly, we also have demonstrated that Rgr expression in thymocytes of transgenic mice induces severe alterations in the development of the thymocytes, which eventually lead to a high incidence of thymic lymphomas. This study demonstrates that oncogenic Rgr can induce expression of p15INK4b and, more importantly, that both Rgr and p15INK4b cooperate in the malignant phenotype in vivo. These findings provide new insights into the tumorigenic role of Rgr as a potent oncogene and show that p15INK4b can act as a tumor suppressor gene.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-03-3389